BNT-325 is under clinical development by BioNTech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase ...
Dec. 9, 2024 — Researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.
While many of these lumps and bumps are harmless growths and considered benign, others could be harbingers of a more serious problem, such as cancer. The word tumor is an umbrella term for a ...